FIVE vs. KNSA
FIVE (Five Below, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. FIVE operates in Specialty Retail (Consumer Cyclical), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, FIVE returned 2.23%/yr vs 37.13%/yr for KNSA. Their 0.16 correlation means their historical movements had little consistent relationship.
Performance
FIVE vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FIVE achieves a 15.27% return, which is significantly lower than KNSA's 80.22% return.
FIVE
- 1D
- -0.93%
- 1M
- 18.88%
- 6M
- 13.30%
- YTD
- 15.27%
- 1Y
- 59.05%
- 3Y*
- 1.59%
- 5Y*
- 2.23%
- 10Y*
- 16.19%
- ALL TIME*
- 16.31%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
FIVE Five Below, Inc. | $216.87M | $218.85M | $257.87M |
| $68.75M | $54.52M | $46.86M |
FIVE vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
FIVE Five Below, Inc. | 15.27% | 79.46% | -50.76% | 20.52% | -14.51% | 18.24% | 36.85% | 24.96% | 40.78% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between FIVE and KNSA is 0.09, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.09 |
Correlation (3Y) Balances recent behavior with more history. | 0.12 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.18 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.16 |
Fundamentals
FIVE:
$12.01B
KNSA:
$5.67B
FIVE:
$7.93
KNSA:
$1.00
FIVE:
27.37
KNSA:
74.38
FIVE:
3.04
KNSA:
0.72
FIVE:
2.37
KNSA:
7.14
FIVE:
5.22
KNSA:
9.48
FIVE:
$5.08B
KNSA:
$840.85M
FIVE:
$1.77B
KNSA:
$546.22M
FIVE:
$757.48M
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FIVE vs. KNSA — Risk / Return Rank
FIVE
KNSA
FIVE vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Five Below, Inc. (FIVE) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FIVE | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.44 | ||
| Sortino ratioReturn per unit of downside risk | -2.18 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.52 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 2.06 | 6.94 | -4.88 |
| Martin ratioReturn relative to average drawdown | 5.93 | 24.13 | -18.20 |
Loading charts...
Drawdowns
FIVE vs. KNSA - Drawdown Comparison
The maximum FIVE drawdown since its inception was -76.40%, smaller than the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for FIVE and KNSA.
Loading charts...
Drawdown Indicators
| FIVE | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -76.40% | -83.06% | +6.66% |
Max Drawdown (1Y)Largest decline over 1 year | -28.85% | -21.12% | -7.73% |
Max Drawdown (3Y)Largest decline over 3 years | -74.13% | -34.14% | -39.99% |
Max Drawdown (5Y)Largest decline over 5 years | -76.40% | -53.17% | -23.23% |
Max Drawdown (10Y)Largest decline over 10 years | -76.40% | — | — |
Current DrawdownCurrent decline from peak | -12.35% | -8.13% | -4.22% |
Average DrawdownAverage peak-to-trough decline | -23.18% | -40.09% | +16.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.00% | 6.06% | +3.94% |
Volatility
FIVE vs. KNSA - Volatility Comparison
The current volatility for Five Below, Inc. (FIVE) is 7.87%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 26.47%. This indicates that FIVE experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FIVE | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.87% | 26.47% | -18.60% |
Volatility (6M)Calculated over the trailing 6-month period | 30.41% | 41.55% | -11.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 39.58% | 49.77% | -10.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 48.04% | 54.77% | -6.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.20% | 64.34% | -18.14% |
Dividends
FIVE vs. KNSA - Dividend Comparison
Neither FIVE nor KNSA has paid dividends to shareholders.
Financials
FIVE vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Five Below, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FIVE vs. KNSA - Profitability Comparison
FIVE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Five Below, Inc. reported a gross profit of 427.52M and revenue of 1.29B. Therefore, the gross margin over that period was 33.3%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
FIVE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Five Below, Inc. reported an operating income of 154.24M and revenue of 1.29B, resulting in an operating margin of 12.0%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
FIVE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Five Below, Inc. reported a net income of 123.06M and revenue of 1.29B, resulting in a net margin of 9.6%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
Frequently Asked Questions
FIVE and KNSA have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (26.47%) compared to FIVE (7.87%). In terms of maximum drawdown, FIVE dropped -76.40% vs KNSA's -83.06%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 1.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FIVE and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer